ReviewBreast cancer (Dove Medical Press)2014
Tamoxifen for women at high risk of breast cancer.
Review in Breast cancer (Dove Medical Press), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Risk-reducing medications for primary breast cancer: a network meta-analysis.The Cochrane database of systematic reviews · 2019Pooled it
- Coping Self-Efficacy and Its Relationship with Psychological Morbidity after Genetic Test Result Disclosure: Results from Cancer-UnaffectedInternational journal of environmental research and public health · 2023Trial
- Compact breast parenchyma: imaging and transcriptomic correlates.Journal of translational medicine · 2026Article
- MAPK signaling mediates tamoxifen resistance in estrogen receptor-positive breast cancer.Molecular and cellular biochemistry · 2025Review
- Behavior of Osteoblastic Lineage Cells When in the Presence of Tamoxifen: In Vitro and In Vivo Studies on Osseointegration.Dentistry journal · 2025Article
- A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia.Cancers · 2025Review
- Molecular Networking, Docking, and Biological Evaluation of Licarin A fromMolecules (Basel, Switzerland) · 2024Article
- Optical Aptamer-Based Cytokine Nanosensor Detects Macrophage Activation by Bacterial Toxins.ACS sensors · 2024Article
- Purification and characterization of the produced hyaluronidase by Brucella Intermedia MEFS for antioxidant and anticancer applications.Microbial cell factories · 2024Article
- Article
- New fluorobenzamidine exerts antitumor activity against breast cancer in mice via pro-apoptotic activity.Discover oncology · 2022Article
- Incidence and Risk Factors for Venous Thromboembolism in Female Patients Undergoing Breast Surgery.Cancers · 2022Article
- Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.Life (Basel, Switzerland) · 2022Article
- Tamoxifen Increased Parasite Burden and Induced a Series of Histopathological and Immunohistochemical Changes During Chronic Toxoplasmosis in Experimentally Infected Mice.Frontiers in microbiology · 2022Article
- Preparation of blueberry anthocyanin liposomes and changes of vesicle properties, physicochemical properties, in vitro release, and antioxidant activity before and after chitosan modification.Food science & nutrition · 2022Article
- Article
- Current State of Breast Cancer Diagnosis, Treatment, and Theranostics.Pharmaceutics · 2021Review
- Sex Hormones in Lymphedema.Cancers · 2021Review
- Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions.Breast cancer research and treatment · 2021Article
- The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications.Health services research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tamoxifen has been used as a treatment for women who have been diagnosed with breast cancer for roughly four decades and has been approved as chemoprevention for over ten years. Although tamoxifen has been proven to be beneficial in preventing breast cancer in high-risk women, its use has not been widely embraced. To some extent, this is due to several of its side effects, including an increased risk of endometrial cancer and pulmonary embolism, but these serious side effects are rare. The risks and benefits of tamoxifen chemoprevention should be considered for each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.